| Product Code: ETC7656989 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Israel saw continued imports of neuroprotective agents from top exporters including Switzerland, UK, Belgium, USA, and Germany. The market displayed low concentration with a low Herfindahl-Hirschman Index (HHI). Despite a slight decline in the Compound Annual Growth Rate (CAGR) from 2020-2024 at -2.14%, the sector remained relatively stable with a marginal decrease in growth rate from 2023-2024 at -0.41%. The consistent flow of imports from diverse sources indicates a steady demand for neuroprotective agents in Israel.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Neuroprotective Agents Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Neuroprotective Agents Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Neuroprotective Agents Market - Industry Life Cycle |
3.4 Israel Neuroprotective Agents Market - Porter's Five Forces |
3.5 Israel Neuroprotective Agents Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Israel Neuroprotective Agents Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Israel Neuroprotective Agents Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Israel Neuroprotective Agents Market Revenues & Volume Share, By Distribution Cahnnel, 2021 & 2031F |
4 Israel Neuroprotective Agents Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in Israel |
4.2.2 Growing awareness about the benefits of neuroprotective agents in preventing neurodegenerative diseases |
4.2.3 Advancements in medical technology and research leading to the development of innovative neuroprotective agents |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of neuroprotective agents in Israel |
4.3.2 High cost associated with neuroprotective agents leading to limited affordability for some patients |
4.3.3 Potential side effects and safety concerns associated with neuroprotective agents |
5 Israel Neuroprotective Agents Market Trends |
6 Israel Neuroprotective Agents Market, By Types |
6.1 Israel Neuroprotective Agents Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Israel Neuroprotective Agents Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Israel Neuroprotective Agents Market Revenues & Volume, By Anesthetics, 2021- 2031F |
6.1.4 Israel Neuroprotective Agents Market Revenues & Volume, By Antagonists, 2021- 2031F |
6.1.5 Israel Neuroprotective Agents Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.6 Israel Neuroprotective Agents Market Revenues & Volume, By Cytokines, 2021- 2031F |
6.1.7 Israel Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Neuroprotective Agents Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Israel Neuroprotective Agents Market Revenues & Volume, By Alzheimer's disease, 2021- 2031F |
6.2.3 Israel Neuroprotective Agents Market Revenues & Volume, By Dementia, 2021- 2031F |
6.2.4 Israel Neuroprotective Agents Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.2.5 Israel Neuroprotective Agents Market Revenues & Volume, By Multiple sclerosis, 2021- 2031F |
6.2.6 Israel Neuroprotective Agents Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Neuroprotective Agents Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Israel Neuroprotective Agents Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Israel Neuroprotective Agents Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 Israel Neuroprotective Agents Market Revenues & Volume, By Epidural, 2021- 2031F |
6.3.5 Israel Neuroprotective Agents Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4 Israel Neuroprotective Agents Market, By Distribution Cahnnel |
6.4.1 Overview and Analysis |
6.4.2 Israel Neuroprotective Agents Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Israel Neuroprotective Agents Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Israel Neuroprotective Agents Market Revenues & Volume, By Drug Stores, 2021- 2031F |
6.4.5 Israel Neuroprotective Agents Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Israel Neuroprotective Agents Market Import-Export Trade Statistics |
7.1 Israel Neuroprotective Agents Market Export to Major Countries |
7.2 Israel Neuroprotective Agents Market Imports from Major Countries |
8 Israel Neuroprotective Agents Market Key Performance Indicators |
8.1 Research and development investment in neuroprotective agents |
8.2 Number of clinical trials conducted for neuroprotective agents in Israel |
8.3 Adoption rate of neuroprotective agents by healthcare professionals in Israel |
8.4 Patient adherence and compliance to neuroprotective agent treatment regimens |
9 Israel Neuroprotective Agents Market - Opportunity Assessment |
9.1 Israel Neuroprotective Agents Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Israel Neuroprotective Agents Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Israel Neuroprotective Agents Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Israel Neuroprotective Agents Market Opportunity Assessment, By Distribution Cahnnel, 2021 & 2031F |
10 Israel Neuroprotective Agents Market - Competitive Landscape |
10.1 Israel Neuroprotective Agents Market Revenue Share, By Companies, 2024 |
10.2 Israel Neuroprotective Agents Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here